Hippocampal protein expression is differentially affected by chronic paroxetine treatment in adolescent and adult rats: A possible mechanism of "paradoxical" antidepressant responses in young persons

Frontiers in Pharmacology

Volumn 4 JUL, Issue , 2013, Pages

  Karanges, Emily A ^a   Kashem, Mohammed A ^a   Sarker, Ranjana ^a   Ahmed, Eakhlas U ^a   Ahmed, Selina ^a   Van Nieuwenhuijzen, Petra S ^a   Kemp, Andrew H ^a   McGregor, Iain S ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Adolescent; Antidepressant; Hippocampus; Paroxetine; Proteomics; Rat

Indexed keywords

ALDEHYDE REDUCTASE; CARBONYL REDUCTASE; CARBONYL REDUCTASE 3; CATHEPSIN B; DRINKING WATER; DYNAMIN I; GALECTIN 7; NEUROGENIN 1; NEUROTRANSMITTER; PAROXETINE; PHOSPHATIDYLINOSITIDE; PHOSPHODIESTERASE; PHOSPHODIESTERASE 10A; PROTEIN BID; PROTEIN KINASE C; SYNTAXIN; SYNTAXIN 7; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT ANIMAL; AGE; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; HIPPOCAMPUS; JUVENILE ANIMAL; MALE; NEUROPROTECTION; NEUROTRANSMITTER RELEASE; NEUROTROPISM; NONHUMAN; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; UPREGULATION;

EID: 84881601136     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2013.00086     Document Type: Article

References (104)

1. Ahmed, E. U., Ahmed, S., Ukai, W., Matsumoto, I., Kemp, A., McGregor, I. S., et al. (2012). Antipsychotic induced alteration of growth and proteome of rat neural stem cells. Neurochem. Res. 37, 1649-1659. doi: 10.1007/s11064-012-0768-3.
2. Antonin, W., Fasshauer, D., Becker, S., Jahn, R., and Schneider, T. R. (2002). Crystal structure of the endosomal SNARE complex reveals common structural principles for all SNAREs. Nat. Struct. Biol. 9, 107-111. doi: 10.1038/nsb746.
3. Artigas, F., Celada, P., Laruelle, M., and Adell, A. (2001). How does pindolol improve antidepressant action? Trends Pharmacol. Sci. 22, 224-228. doi: 10.1016/S0165-6147(00)01682-5.
4. Avissar, S., and Schreiber, G. (1994). Antidepressant and antibipolar treatments' effects on receptor-coupled G proteins measures in lymphocytes of patients with mood disorders. Neuropsychopharmacology 10, 170S.
5. Avissar, S., and Schreiber, G. (2006). The involvement of G proteins and regulators of receptor-G protein coupling in the pathophysiology, diagnosis and treatment of mood disorders. Clinica Chimica Acta 366, 37-47. doi: 10.1016/j.cca.2005.11.003.
6. Bilici, M., Efe, H., Koroglu, M. A., Uydu, H. A., Bekaroglu, M., and Deger, O. (2001). Antioxidant enzymes and lipid peroxidation in major depression: alterations by antidepressant treatment. J. Affect. Disord. 64, 43-51. doi: 10.1016/S0165-0327(00)00199-3.
7. Bogunovic, B., Stojakovic, M., Chen, L., and Maric, M. (2008). An unexpected functional link between lysosome thiol reductase and mitochondrial manganese superoxide dismutase. J. Biol. Chem. 283, 8855-8862. doi: 10.1074/jbc.M708998200.
8. Bosker, F. J., Klompmakers, A. A., and Westenberg, H. G. M. (1995). Effects of single and repeated oral administration of fluvoxamine on extracellular serotonin in the median raphe nucleus and dorsal hippocampus of the rat. Neuropharmacology 34, 501-508. doi: 10.1016/0028-3908(95)00023-Y.
9. Botella, J. A., Ulschmid, J. K., Gruenewald, C., Moehle, C., Kretzschmar, D., Becker, K., et al. (2004). The Drosophila carbonyl reductase Sniffer prevents oxidative stress-induced neurodegeneration. Curr. Biol. 14, 782-786. doi: 10.1016/j.cub.2004.04.036
10. Bradford, M. M. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248-254. doi: 10.1016/0003-2697(76)90527-3.
11. Carlson, J. N., Visker, K. E., Mielsen, D. M., Keller, R. W. Jr., and Glick, S. D. (1996). Chronic antidepressant drug treatment reduces turning behavior and increases dopamine levels in the medial prefrontal cortex. Brain Res. 707, 122-126. doi: 10.1016/0006-8993(95)01341-5.
12. Carrasco, J. L., and Sandner, C. (2005). Clinical effects of pharmacological variations in selective serotonin reuptake inhibitors: an overview. Int. J. Clin. Pract. 59, 1428-1434. doi: 10.1111/j.1368-5031.2005.00681.x.
13. Chang, T. K. H., Chen, J., Yang, G., and Yeung, E. Y. H. (2010). Inhibition of procarcinogen-bioactivating human CYP1A1, CYP1A2 and CYP1B1 enzymes by melatonin. J. Pineal Res. 48, 55-64. doi: 10.1111/j.1600-079X.2009.00724.x.
14. Chen, B., Dowlatshahi, D., Macqueen, G. M., Wang, J. F., and Young, L. T. (2001). Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol. Psychiatry 50, 260-265. doi: 10.1016/S0006-3223(01)01083-6.
15. Cheung, A. H., Emslie, G. J., and Mayes, T. L. (2005). Review of the efficacy and safety of antidepressants in youth depression. J. Child Psychol. Psychiatry 46, 735-754. doi: 10.1111/j.1469-7610.2005.01467.x.
16. Crews, F., He, J., and Hodge, C. (2007). Adolescent cortical development: a critical period of vulnerability for addiction. Pharmacol. Biochem. Behav. 86, 189-199. doi: 10.1016/j.pbb.2006.12.001.
17. Delago, P. L. (2004). How antidepressants help depression: mechanisms of action and clincial response. J. Clin. Psychiatry 65, S25-S30.
18. DeVane, C. L. (1999). Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors. Cell. Mol. Neurobiol. 19, 443-466. doi: 10.1023/A:1006934807375.
19. Di Giovanni, G., Di Matteo, V., Pierucci, M., and Esposito, E. (2008). Serotonin-dopamine interaction: electrophysiological evidence. Prog. Brain Res. 172, 45-71. doi: 10.1016/S0079-6123(08)00903-5.
20. Drzyzga, L. R., Marcinowska, A., and Obuchowicz, E. (2009). Antiapoptotic and neurotophic effects of antidepressants: a review of clinical and experimental studies. Brain Res. Bull. 79, 248-257. doi: 10.1016/j.brainresbull.2009.03.009.
21. Duman, R. S., and Monteggia, L. M. (2006). A neurotrophic model for stress-related mood disorders. Biol. Psychiatry 59, 1116-1127. doi: 10.1016/j.biopsych.2006.02.013.
22. Dutheil, F., Beaune, P., and Loriot, M.-A. (2008). Xenobiotic metabolizing enzymes in the central nervous system: contribution of cytochrome P450 enzymes in normal and pathological human brain. Biochimie 90, 426-436. doi: 10.1016/j.biochi.2007.10.007.
23. Dwivedi, Y., Mondal, A. C., Shukla, P. K., Rizavi, H. S., and Lyons, J. (2004a). Altered protein kinase A in brain of learned helpless rats: effects of acute and repeated stress. Biol. Psychiatry 56, 30-40. doi: 10.1016/j.biopsych.2004.03.018.
24. Dwivedi, Y., Rizavi, H. S., Shukla, P. K., Lyons, J., Falidu, G., Palkovits, M., et al. (2004b). Protein kinase A in postmortem brain of depressed suicide victims: altered expression of specific regulatory and catalytic subunits. Biol. Psychiatry 55, 234-243. doi: 10.1016/j.biopsych.2003.11.003.
25. Dwivedi, Y., and Pandey, G. N. (2011). Elucidating biological risk factors in suicide: role of protein kinase A. Prog. Neuropsychopharmacol. Biol. Psychiatry 35, 831-841. doi: 10.1016/j.pnpbp.2010.08.025.
26. Ellis, E. M. (2007). Reactive carbonyls and oxidative stress: potential for therapeutic intervention. Pharmacol. Ther. 115, 13-24. doi: 10.1016/j.pharmthera.2007.03.015.
27. Esposito, K., Reierson, G. W., Luo, H. R., Wu, G. S., Licino, J., and Wong, M.-L. (2009). Phosphodiesterase genes and antidepressant treatment response: a review. Ann. Med. 41, 177-185. doi: 10.1080/07853890802441169.
28. Fava, M., and Kendler, K. S. (2000). Major depressive disorder. Neuron 28, 335-341. doi: 10.1016/S0896-6273(00)00112-4.
29. Feldmann, R. E. J., Sawa, A., and Seidler, G. H. (2007). Causality of stem cell based neurogenesis and depression - To be or not to be, is that the question? J. Psychiatr. Res. 41, 713-723. doi: 10.1016/j.jpsychires.2006.06.007.
30. Fleming, G. F. (2007). The mental health of adolescents: assessment and management. Aust. Fam. Physician 36, 588-593.
31. Fontella, F. U., Siqueira, I. R., Vasconcellos, A. P. S., Tabajara, A. S., Netto, C. A., and Dalmaz, C. (2005). Repeated restraint stress induces oxidative damage in rat hippocampus. Neurochem. Res. 31, 105-111. doi: 10.1007/s11064-004-9691-6.
32. Frazer, A. (1997). Pharmacology of antidepressants. J. Clin. Psychopharmacol. 17, 2S-18S. doi: 10.1097/00004714-199704001-00002.
33. Galfalvy, H., Huang, Y. Y., Oquendo, M. A., Currier, D., and Mann, J. J. (2009). Increased risk of suicide attempt in mood disorders and TPH1 genotype. J. Affect. Disord. 115, 331-338. doi: 10.1016/j.jad.2008.09.019.
34. Gibbons, R. D., Brown, C. H., Hur, K., Marcus, S. M., Bhaurnik, D. K., Erkens, J. A., et al. (2007). Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am. J. Psychiatry 164, 1356-1363. doi: 10.1176/appi.ajp.2007.07030454.
35. Gizatullin, R., Zaboli, G., Jonsson, E. G., Asberg, M., and Leopardi, R. (2006). Haplotype analysis reveals tryptophan hydroxylase (TPH) 1 gene variants associated with major depression. Biol. Psychiatry 59, 295-300. doi: 10.1016/j.biopsych.2005.07.034.
36. Goodman, Y., Bruce, A. J., Cheng, B., and Mattson, M. P. (1996). Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury, and amyloid β-peptide toxicity in hippocampal neurons. J. Neurochem. 66, 1836-1844. doi: 10.1046/j.1471-4159.1996.66051836.x.
37. Gould, T. D., and Manji, H. K. (2002). Signaling networks in the pathophysiology and treatment of mood disorders. J. Psychosom. Res. 53, 687-697. doi: 10.1016/S0022-3999(02)00426-9.
38. Guicciardi, M. E., Deussing, J., Miyoshi, H., Bronk, S. F., Svingen, P. A., Peters, C., et al. (2000). Cathepsin B contributes to TNF-α-mediated hepatocyte apoptosis by promoting mitochondrial release of cytochrome c. J. Clin. Invest. 106, 1127-1137. doi: 10.1172/JCI9914.
39. Halliwell, B. (2001). Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment. Drugs Aging 18, 685-716. doi: 10.2165/00002512-200118090-00004.
40. Ham, B. J., Lee, B. C., Paik, J. W., Kang, R. H., Choi, M. J., Choi, I. G., et al. (2007). Association between the tryptophan hydroxylase-1 gene A218C polymorphism and citalopram antidepressant treatment response in a Korean population. Prog. Neuropsychopharmacol. Biol. Psychiatry 31, 104-107. doi: 10.1016/j.pnpbp.2006.08.001.
41. Hammad, T. A., Laughren, T., and Racoosin, J. (2006). Suicidality in pediatric patients treated with antidepressant drugs. Arch. Gen. Psychiatry 63, 332-339. doi: 10.1001/archpsyc.63.3.332.
42. Härtter, S., Wang, X., Weigmann, H., Friedberg, T., Arand, M., Oesch, F., et al. (2001). Differential effects of fluvoxamine and other antidepressants on the biotransformation of melatonin. J. Clin. Psychopharmacol. 21, 167-174. doi: 10.1097/00004714-200104000-00008.
43. Hensler, J. G. (2003). Regulation of 5-HT1A receptor function in brain following agonist or antidepressant administration. Life Sci. 72, 1665-1682. doi: 10.1016/S0024-3205(02)02482-7.
44. Hodes, G. E., Yang, L., Van Kooy, J., Santollo, J., and Shors, T. J. (2009). Prozac during puberty: distinctive effects on neurogenesis as a function of age and sex. Neuroscience 163, 609-617. doi: 10.1016/j.neuroscience.2009.06.057.
45. Hyman, S. E. (2006). Even chromatin gets the blues. Nat. Neurosci. 9, 465-466. doi: 10.1038/nn0406-465.
46. Jiang, W., Uht, R., and Bohn, M. C. (1989). Regulation of phenylethanolamine N-methyltransferase (PNMT) mRNA in the rat adrenal medulla by corticosterone. Int. J. Dev. Neurosci. 7, 513-520. doi: 10.1016/0736-5748(89)90010-5.
47. Karanges, E., Li, K. M., Motbey, C., Callaghan, P., Kastifis, A., and McGregor, I. S. (2011). Differential behavioural and neurochemical outcomes from chronic paroxetine treatment in adolescent and adult rats: a model of adverse antidepressant effects in human adolescents? Int. J. Neuropsychopharmacol. 14, 491-504. doi: 10.1017/S146114571100006X.
48. Kashem, M. A., Ahmed, S., Sarker, R., Ahmed, E. U., Hargreaves, G. A., and McGregor, I. S. (2012). Long-term daily access to alcohol alters dopamine-related synthesis and signalling proteins in the rat striatum. Neurochem. Int. 61, 1280-1288. doi: 10.1016/j.neuint.2012.08.013.
49. Khundakar, A. A., and Zetterström, T. S. C. (2006). Biphasic change in BDNF expression following antidepressant drug treatment explained by differential transcript regulation. Brain Res. 1106, 12-20. doi: 10.1016/j.brainres.2006.05.063.
50. Korsten, T. A., Galloway, M. P., Duman, R. S., Russell, D. S., and D'sa, C. (2008). Repeated unpredictable stress and antidepressants differentially regulate expression of the Bcl-2 family of apoptotic genes in rat cortical, hippocampal and limbic brain structures. Neuropsychopharmacology 33, 1545-1558. doi: 10.1038/sj.npp.1301527.
51. Li, Y.-F., Huang, Y., Amsdell, S. L., Xiao, L., O'Donnell, J. M., and Zhang, H.-T. (2009). Antidepressant- and anxiolytic-like effects of the phosphodiesterase-4 inhibitor rolipram on behavior depend on cyclic AMP response element binding protein-mediated neurogenesis in the hippocampus. Neuropsychopharmacology 34, 2404-2419. doi: 10.1038/npp.2009.66.
52. Maes, M., Scharpè, S., Meltzer, H. Y., Okayli, G., Bosmans, E., D'Hondt, P., et al. (1994). Increased neopterin and interferon-gamma secretion and lower availability of L-tryptophan in major depression: further evidence for an immune response. Psychiatry Res. 54, 143-160. doi: 10.1016/0165-1781(94)90003-5.
53. Maharaj, D. S., Maharaj, H., Daya, S., and Glass, B. D. (2006). Melatonin and 6-hydroxymelatonin protect against iron-induced neurotoxicity. J. Neurochem. 96, 78-81. doi: 10.1111/j.1471-4159.2005.03532.x.
54. Malkesman, O., Tragon, T., Reed, J. C., Maurizio, P., Chen, G., and Manji, H. K. (2009). Bid inhibitors as potential novel antidepressant drugs. Biol. Psychiatry 64, 75S.
55. Mant, A., Rendle, V. A., Hall, W. D., Mitchell, P. B., Montgomery, W. S., McManus, P. R., and Hickie, I. B. (2004). Making new choices about antidepressants in Australia: the long view 1975-2002. Med. J. Aust. 181, S21-S24.
56. Maser, E. (2006). Neuroprotective role for carbonyl reductase? Biochem. Biophys. Res. Commun. 340, 1019-1022. doi: 10.1016/j.bbrc.2005.12.113.
57. Mason, S. S., Baker, K. B., Davis, K. W., Pogorelov, V. M., Malbari, M. M., Ritter, R., et al. (2009). Differential sensitivity to SSRI and tricyclic antidepressants in juvenile and adult mice of three strains. Eur. J. Pharmacol. 602, 306-315. doi: 10.1016/j.ejphar.2008.11.010.
58. McCormick, C., and Mathews, I. Z. (2010). Adolescent development, hypothalamic-pituitary-adrenal function, and programming of adult learning and memory. Prog. Neuropsychopharmacol. Biol. Psychiatry 34, 756-765. doi: 10.1016/j.pnpbp.2009.09.019.
59. McEwen, B. S. (2001). Plasticity of the hippocampus: adaptation to chronic stress and allostatic load. Ann. N.Y. Acad. Sci. 933, 265-277. doi: 10.1111/j.1749-6632.2001.tb05830.x.
60. McHugh, P. C., Rogers, G. R., Glubb, D. M., Joyce, P. R., and Kennedy, M. A. (2010). Proteomic analysis of rat hippocampus exposed to the antidepressant paroxetine. J. Psychopharmacol. 24, 1243-1251. doi: 10.1177/0269881109102786.
61. McHugh, P. C., Rogers, G. R., Loudon, B., Glubb, D. M., Joyce, P. R., and Kennedy, M. A. (2008). Proteomic analysis of embryonic stem cell-derived neural cells exposed to the antidepressant paroxetine. J. Neurosci. Res. 86, 306-316. doi: 10.1002/jnr.21482.
62. McKernan, D. P., Dinan, T. H., and Cryan, J. F. (2009). "Killing the blues": a role for cellular suicide (apoptosis) in depression and the antidepressant response? Prog. Neurobiol. 88, 246-263. doi: 10.1016/j.pneurobio.2009.04.006.
63. Miksys, S. L., and Tyndale, R. F. (2002). Drug-metabolising cytochrome P450s in the brain. J. Psychiatry Neurosci. 27, 406-415.
64. Mortensen, O. V., Larsen, M. B., Prasad, B. M., and Amara, S. G. (2008). Genetic complementation screen identifies a mitogen-activated protein kinase phosphatase, MKP3, as a regulator of dopamine transporter trafficking. Mol. Biol. Cell 19, 2818-2829. doi: 10.1091/mbc.E07-09-0980.
65. Murray, F., and Hutson, P. H. (2007). Hippocampal Bcl-2 expression is selectively increased following chronic but not acute treatment with antidepressants, 5-HT1A or 5-HT2C/2B receptor antagonists. Eur. J. Pharmacol. 569, 41-47. doi: 10.1016/j.ejphar.2007.05.006.
66. Murrin, L. C., Sanders, J. D., and Bylund, D. B. (2007). Comparison of the maturation of the adrenergic and serotonergic neurotransmitter systems in the brain: implications for differential drug effects on juveniles and adults. Biochem. Pharmacol. 73, 1225-1236. doi: 10.1016/j.bcp.2007.01.028.
67. Nakamura, K., Sugawara, Y., Sawabe, K., Ohashi, A., Tsurui, H., Xiu, Y., et al. (2006). Late developmental stage-specific role of tryptophan hydroxylase 1 in brain serotonin levels. J. Neurosci. 26, 530-534. doi: 10.1523/JNEUROSCI.1835-05.2006.
68. Nathan, P. J., Burrows, G. D., and Norman, T. R. (1998). Evidence for 5-HT1A receptor control of pineal melatonin concentrations in the rat. Eur. Neuropsychopharmacol. 8, 183-186. doi: 10.1016/S0924-977X(97)00060-6.
69. Nibuya, M., Nestler, E. J., and Duman, R. S. (1996). Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J. Neurosci. 16, 2365-2372.
70. Nishizuka, Y. (1992). Intracellular signalling by hydrolysis of phospholipids and activation of protein kinase C. Science 258, 607-614. doi: 10.1126/science.1411571.
71. Oh, J.-E., Zupan, B., Gross, S., and Toth, M. (2009). Paradoxical anxiogenic response of juvenile mice to fluoxetine. Neuropsychopharmacology 34, 2197-2207. doi: 10.1038/npp.2009.47.
72. Otomo, M., Takahashi, K., Miyoshi, H., Osada, K., Nakashima, H., and Yamaguchi, N. (2008). Some selective serotonin reuptake inhibitors inhibit dynamin 1 guanosine triphosphatase (GTPase). Biol. Pharm. Bull. 31, 1489-1495. doi: 10.1248/bpb.31.1489.
73. Owens, M. J., Knight, D. L., and Nemeroff, C. B. (2000). Paroxetine binding to the rat norepinephrine transporter in vivo. Biol. Psychiatry 47, 842-845. doi: 10.1016/S0006-3223(99)00314-5.
74. Paez-Pereda, M. (2005). New drug targets in the signaling pathways activated by antidepressants. Prog. Neuropsychopharmacol. Biol. Psychiatry 29, 1010-1016. doi: 10.1016/j.pnpbp.2005.03.017.
75. Pandey, G. N., Dwivedi, Y., Pandey, S. C., Conley, R. R., Roberts, R. C., and Tamminga, C. A. (1997). Protein kinase C in the postmortem brain of teenage suicide victims. Neurosci. Lett. 228, 111-114. doi: 10.1016/S0304-3940(97)00378-9.
76. Pandey, G. N., Dwivedi, Y., Ren, X., Rizavi, H. S., Mondal, A. C., Shukla, P. K., et al. (2005). Brain region specific alterations in the protein and mRNA levels of protein kinase A subunits in the post-mortem brain of teenage suicide victims. Neuropsychopharmacology 30, 1548-1556. doi: 10.1038/sj.npp.1300765.
77. Pandey, G. N., Dwivedi, Y., Rizavi, H. S., Ren, X., and Conley, R. R. (2004). Decreased catalytic activity and expression of protein kinase C isoforms in teenage suicide victims. Arch. Gen. Psychiatry 61, 685-693. doi: 10.1001/archpsyc.61.7.685.
78. Pappin, D. J. C, Hojrup, P., and Bleasby, A. J. (1993). Rapid identification of proteins by peptide-mass fingerprinting. Curr. Biol. 3, 327-332. doi: 10.1016/0960-9822(93)90195-T.
79. Pariante, C. M., and Lightman, S. L. (2008). The HPA axis in major depression: Classical theories and new developments. Trends Neurosci. 31, 464-468. doi: 10.1016/j.tins.2008.06.006.
80. Paus, T. (2005). Mapping brain maturation and cognitive development through adolescence. Trends Cogn. Sci. 9, 61-68. doi: 10.1016/j.tics.2004.12.008.
81. Pooley, E. C., Houston, K., Hawton, K., and Harrison, P. J. (2003). Deliberate self-harm is associated with allelic variation in the tryptophan hydroxylase gene (TPH A779C), but not with polymorphisms in five other serotonergic genes. Psychol. Med. 33, 775-873. doi: 10.1017/S0033291703007463.
82. Popoli, M., Mori, S., Brunello, N., Perez, J., Gennarelli, M., and Racagni, G. (2001). Serine/threonine kinases as molecular targets of antidepressants: implications for pharmacological treatment and pathophysiology of affective disorders. Pharmacol. Ther. 89, 149-170. doi: 10.1016/S0163-7258(00)00108-X.
83. Rainey, M. M., Korostyshevsky, D., Lee, S., and Perlstein, E. O. (2010). The antidepressant sertraline targets intracellular vesiculogenic membranes in yeast. Genetics 185, 1221-1233. doi: 10.1534/genetics.110.117846.
84. Reierson, G. W., Mastronardi, C. A., Licino, J., and Wong, M.-L. (2009). Repeated antidepressant therapy increases cyclic GMP signaling in rat hippocampus. Neurosci. Lett. 466, 149-153. doi: 10.1016/j.neulet.2009.09.047.
85. Rizo, J., Chen, X., and Araç, D. (2006). Unraveling the mechanisms of synaptotagmin and SNARE in neurotransmitter release. Trends Cell Biol. 16, 339-350. doi: 10.1016/j.tcb.2006.04.006.
86. Sabban, E. L., Hiremagalur, B., Nankova, B., and Kvetnansky, R. (1995). Molecular biology of stress-elicited induction of catecholamine biosynthetic enzymes. Ann. N.Y. Acad. Sci. 771, 327-338. doi: 10.1111/j.1749-6632.1995.tb44692.x.
87. Santarelli, L., Saxe, M., Gross, C., Surget, A., Battaglia, F., Dulawa, S., et al. (2003). Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 301, 805. doi: 10.1126/science.1083328.
88. Satoh, J.-I., Obayashi, S., Misawa, T., Tabunoki, H., Yamamura, T., Arima, K., et al. (2008). Neuromyelitis optica/Devic's disease: Gene expression profiling of brain lesions. Neuropathology 28, 561-576.
89. Saussez, S., and Kiss, R. (2006). Galectin-7. Cell. Mol. Life Sci. 63, 686-697. doi: 10.1007/s00018-005-5458-8.
90. Sillaber, I., Panhuysen, M., Henniger, M. S. H., Ohl, F., Kühne, C., Pütz, B., et al. (2008). Profiling of behavioural changes and hippocampal gene expression in mice chronically treated with the SSRI paroxetine. Psychopharmacology 200, 557-572. doi: 10.1007/s00213-008-1232-6.
91. Spasojevic, N., Gavrilovic, L., and Dronjak, S. (2010). Effects of repeated maprotiline and fluoxetine treatment on gene expression of catecholamine synthesizing enzymes in adrenal medulla of unstressed and stressed rats. Auton. Autacoid Pharmacol. 30, 213-217. doi: 10.1111/j.1474-8673.2010.00458.x.
92. Spear, L. P. (2007). Assessment of adolescent neurotoxicity: rationale and methodological considerations. Neurotoxicol. Teratol. 29, 1-9. doi: 10.1016/j.ntt.2006.11.006.
93. Stoka, V., Turk, B., Schendel, S. L., Kim, T.-H., Cirman, T., Snipas, S. J., et al. (2001). Lysosomal protease pathways to apoptosis. Cleavage of Bid, not pro-caspases, is the most likely route. J. Biol. Chem. 276, 3149-3157. doi: 10.1074/jbc.M008944200.
94. Stone, M., Laughren, T., Jones, M. L., Levenson, M., Holland, C. P., Hughes, A., et al. (2009). Risk of suicidality in clinical trials of antidepressants in adults: Analysis of proprietary data submitted to US Food and Drug Administration. BMJ 339, b2880. doi: 10.1136/bmj.b2880.
95. Takahashi, M., Terwilliger, R., Lane, C., Mezes, P. S., Conti, M., and Dunman, R. S. (1999). Chronic antidepressant administration increases the expression of cAMP-specific phosphodiesterase 4A and 4B isoforms. J. Neurosci. 19, 610-618.
96. Thompson, M. R., Li, K. M., Clemens, K. J., Gurtman, C. G., Hunt, G. E., Cornish, J. L., et al. (2004). Chronic fluoxetine treatment partly attenuates the long-term anxiety and depressive symptoms induced by MDMA ('ecstasy') in rats. Neuropsychopharmacology 29, 694-704. doi: 10.1038/sj.npp.1300347.
97. Tsapakis, E. M., Soldani, F., Tondo, L., and Baldessarini, R. J. (2008). Efficacy of antidepressants in juvenile depression: meta-analysis. Br. J. Psychiatry 193, 10-17. doi: 10.1192/bjp.bp.106.031088.
98. Whittington, C. J., Kendall, T., Fonagy, P., Cottrell, D., Cotgrove, A., and Boddington, E. (2004). Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 363, 1341-1345. doi: 10.1016/S0140-6736(04)16043-1.
99. Wong, M.-L., Whelan, F., Deloukas, P., Whittaker, P., Delgado, M., Cantor, R. M., et al. (2006). Phosphodiesterase genes are associated with susceptibility to major depression and antidepressant treatment response Proc. Natl. Acad. Sci. U.S.A. 103, 15124-15129. doi: 10.1073/pnas.0602795103.
100. Wu, L., Peng, J., Wei, C., Liu, G., Wang, G., Li, K., et al. (2010). Characterization, using comparative proteomics, of differentially expressed proteins in the hippocampus of the mesial temporal lobe of epileptic rats following treatment with valproate. Amino Acids 40, 221-238. doi: 10.1007/s00726-010-0638-8.
101. Yamauchi, M., Tatebayashi, T., Nagase, K., Kojima, M., and Imanishi, T. (2004). Chronic treatment with fluvoxamine desensitizes 5-HT2C receptor-mediated hypolocomotion in rats. Pharmacol. Biochem. Behav. 78, 683-689. doi: 10.1016/j.pbb.2004.05.003.
102. Zafir, A., Ara, A., and Banu, N. (2009). In vivo antioxidant status: a putative target of antidepressant action. Prog. Neuropsychopharmacol. Biol. Psychiatry 33, 220-228. doi: 10.1016/j.pnpbp.2008.11.010.
103. Zarate, C. A., and Manji, H. K. (2009). Protein kinase C inhibitors: rationale for use and potential in the treatment of bipolar disorder. CNS Drugs 23, 569-582. doi: 10.2165/00023210-200923070-00003.
104. Zhang, J., Zhang, W., Zou, D., Chen, G., Wan, T., Zhang, M., et al. (2003). Cloning and functional characterization of GMPR2, a novel human guanosine monophosphate reductase, which promotes the monocytic differentiation of HL-60 leukemia cells. J. Cancer Res. Clin. Oncol. 129, 76-83.